SG3 Management’s State Street SPDR S&P Biotech ETF XBI Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2022
Q4
Sell
-2,300
Closed -$182K 345
2022
Q3
$182K Buy
+2,300
New +$194K 0.02% 203
2020
Q3
Sell
-10,000
Closed -$1.12M 1089
2020
Q2
$1.12M Hold
10,000
0.08% 271
2020
Q1
$774K Buy
+10,000
New +$885K 0.1% 124
2017
Q3
Sell
-20,000
Closed -$1.54M 263
2017
Q2
$1.54M Buy
+20,000
New +$1.42M 0.39% 70

Other funds holding XBI

SG3 Management's XBI Position: Q3 2020 in Review

SG3 Management sold out of State Street SPDR S&P Biotech ETF (XBI) in Q3 2020, closing a stake of 3,000 shares — an estimated $336K sold.

SG3 Management first reported a position in XBI in Q2 2020 and held it in 1 quarter. The position peaked at $336K in Q2 2020. 554 funds tracked by Wall St. Rank hold XBI as of Q3 2020.

  • SG3 Management reported no remaining State Street SPDR S&P Biotech ETF position as of Q3 2020 after selling out during the quarter.
  • SG3 Management sold 3,000 State Street SPDR S&P Biotech ETF shares in Q3 2020, an estimated $336K.
  • SG3 Management first reported a position in State Street SPDR S&P Biotech ETF in Q2 2020 and held it in 1 quarter.
  • SG3 Management's State Street SPDR S&P Biotech ETF position peaked at $336K in Q2 2020.
  • 554 funds tracked by Wall St. Rank held State Street SPDR S&P Biotech ETF as of Q3 2020.

Based on SG3 Management's 13F filing for Q3 2020, filed 13 Nov 2020.